Immunogenicity of Mycobacterium ulcerans Hsp65 and protective efficacy of a Mycobacterium leprae Hsp65-based DNA vaccine against Buruli ulcer

被引:37
作者
Coutanceau, Emmanuelle
Legras, Pierre
Marsollier, Laurent
Reysset, Gilles
Cole, Stewart T.
Demangel, Caroline
机构
[1] Inst Pasteur, Unite Genet Mol Bacterienne, F-75724 Paris 15, France
[2] CHU Angers, Anim Hosp Univ, Angers, France
关键词
Mycobacterium ulcerans; Buruli ulcer; Hsp65; vaccination;
D O I
10.1016/j.micinf.2006.03.009
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Buruli ulcer, a disease caused by Mycobacterium ulcerans, is emerging as an increasingly important cause of morbidity throughout the world, for which surgery is the only efficient treatment to date. The aim of this work was to identify potential vaccine candidates in an experimental model of mouse infection. In BALB/c mice infected with M. ulcerans subcutaneously, Hsp65 appeared to be an immunodominant antigen eliciting both Immoral and cellular responses. However, vaccination of mice with a DNA vector encoding Mycobacterium leprae Hsp65 only poorly limited the progression of M. ulcerans infection. In contrast, a substantial degree of protection was conferred by subcutaneous vaccination with BCG, suggesting that BCG antigens that are conserved in M. ulcerans, such as TB 10.4, the 19 kDa antigen, PstS3 and Hsp70, may be interesting to consider as subunit vaccines in future prospects. (c) 2006 Elsevier SAS. All rights reserved.
引用
收藏
页码:2075 / 2081
页数:7
相关论文
共 19 条
[1]   Modulation of the host immune response by a transient intracellular stage of Mycobacterium ulcerans:: the contribution of endogenous mycolactone toxin [J].
Coutanceau, E ;
Marsollier, L ;
Brosch, R ;
Perret, E ;
Goossens, P ;
Tanguy, M ;
Cole, ST ;
Small, PLC ;
Demangel, C .
CELLULAR MICROBIOLOGY, 2005, 7 (08) :1187-1196
[2]   Mapping of murine Th1 helper T-cell epitopes of mycolyl transferases Ag85A, Ag85B, and Ag85C from Mycobacterium tuberculosis [J].
D'Souza, S ;
Rosseels, V ;
Romano, A ;
Tanghe, A ;
Denis, O ;
Jurion, P ;
Castiglione, N ;
Vanonckelen, A ;
Palfliet, K ;
Huygen, K .
INFECTION AND IMMUNITY, 2003, 71 (01) :483-493
[3]   Serologic response to culture filtrate antigens of Mycobacterium ulcerans during Buruli ulcer disease [J].
Dobos, KM ;
Spotts, EA ;
Marston, BJ ;
Horsburgh, CR ;
King, CH .
EMERGING INFECTIOUS DISEASES, 2000, 6 (02) :158-164
[4]   Efficacy of the combination rifampin-streptomycin in preventing growth of Mycobacterium ulcerans in early lesions of buruli ulcer in humans [J].
Etuaful, S ;
Carbonnelle, B ;
Grosset, J ;
Lucas, S ;
Horsfield, C ;
Phillips, R ;
Evans, A ;
Ofori-Adjei, D ;
Klustse, E ;
Owusu-Boaten, J ;
Amedofu, GK ;
Awuah, P ;
Arnpadu, E ;
Amofah, G ;
Asiedu, K ;
Wansbrough-Jones, A .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2005, 49 (08) :3182-3186
[5]  
FENNER F, 1957, AM REV TUBERC PULM, V76, P76
[6]   Mycolactone:: A polyketide toxin from Mycobacterium ulcerans required for virulence [J].
George, KM ;
Chatterjee, D ;
Gunawardana, G ;
Welty, D ;
Hayman, J ;
Lee, R ;
Small, PLC .
SCIENCE, 1999, 283 (5403) :854-857
[7]   Acquired T-helper 1 lymphocyte anergy following infection with Mycobacterium ulcerans [J].
Gooding, TM ;
Kemp, AS ;
Robins-Browne, RM ;
Smith, M ;
Johnson, PDR .
CLINICAL INFECTIOUS DISEASES, 2003, 36 (08) :1076-1077
[8]   Cytokine profiles of patients infected with Mycobacterium ulcerans and unaffected household contacts [J].
Gooding, TM ;
Johnson, PDR ;
Smith, M ;
Kemp, AS ;
Robins-Browne, RM .
INFECTION AND IMMUNITY, 2002, 70 (10) :5562-5567
[9]   Immune response to infection with Mycobacterium ulcerans [J].
Gooding, TM ;
Johnson, PDR ;
Campbell, DE ;
Hayman, JA ;
Hartland, EL ;
Kemp, AS ;
Robins-Browne, RM .
INFECTION AND IMMUNITY, 2001, 69 (03) :1704-1707
[10]  
Johnson PDR, 2005, PLOS MED, V2, P282, DOI 10.1371/journal.pmed.0020108